TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.
Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is: to determine the safety, (local) tolerability and plasma
exposure over time of single intramuscular (IM) doses of 600 and 1200 mg of a new formulation
(F006) of TMC278LA, to determine the safety, (local) tolerability and long-term plasma
exposure over time of 2 dose regimens of 4 monthly IM doses of a new formulation (F006) of
TMC278LA., To determine the safety, (local) tolerability and long-term plasma exposure over
time of 1 dose regimen of 4 monthly subcutaneous (SC) doses of a new formulation (F006) of
TMC278LA.